Semaglutide uye Tirzepatide miviri mitsva yeGLP-1-yakavakirwa mishonga inoshandiswa kurapa rudzi rwechipiri chirwere cheshuga uye kufutisa.
Semaglutide yakaratidza mhedzisiro yepamusoro mukuderedza HbA1c mazinga nekusimudzira uremu. Tirzepatide, inova mbiri mbiri GIP/GLP-1 receptor agonist, yakabvumidzwawo neUS FDA neEuropean EMA kurapwa kwemhando yechipiri chirwere cheshuga.
Efficacy
Zvose semaglutide uye tirzepatide zvinogona kuderedza zvakanyanya mazinga eHbA1c kune varwere vane chirwere cheshuga chechipiri, nokudaro kuvandudza kudzora shuga yeropa.
Panyaya yekurasikirwa uremu, tirzepatide inowanzoratidza mhedzisiro iri nani kana ichienzaniswa nesemaglutide.
Cardiovascular Risk
Semaglutide yakaratidza mabhenefiti emwoyo muyedzo yeSUSTAIN-6, kusanganisira njodzi dzakaderedzwa dzekufa kwemoyo, isina-inouraya myocardial infarction, uye isina-inouraya sitiroko.
Tirzepatide's cardiovascular effects inoda kumwe kudzidza, kunyanya mhedzisiro kubva muyedzo yeSURPASS-CVOT.
Kubvumirwa Nezvinodhaka
Semaglutide yakabvumidzwa seyakagadziriswa pakudya uye kurovedza muviri kuvandudza kudzora shuga yeropa muvanhu vakuru vane Type 2 chirwere cheshuga, uye kuderedza njodzi yezviitiko zvakakura zvemoyo muvanhu vakuru vane Type 2 chirwere cheshuga uye vakagadzira chirwere chemoyo.
Tirzepatide yakabvumidzwa seyakagadziriswa kune yakaderedzwa-koriori yekudya uye yakawedzera basa remuviri rekusingaperi uremu manejimendi kune vanhu vakuru vane kufutisa kana kuwandisa uye kanenge kamwe-inoenderana nehuremu comorbidity.
Administration
Ose semaglutide uye tirzepatide anowanzo kupihwa kuburikidza ne subcutaneous jekiseni.
Semaglutide inewo inowanika yemuromo yekugadzira.
Nguva yekutumira: Jul-08-2025